Shilpa Medicare Ltd
NSE:SHILPAMED
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shilpa Medicare Ltd
NSE:SHILPAMED
|
IN |
|
S
|
Sungei Bagan Rubber Company Malaya Bhd
KLSE:SBAGAN
|
MY |
|
C
|
Cubic Sensor and Instrument Co Ltd
SSE:688665
|
CN |
|
UTZ Brands Inc
NYSE:UTZ
|
US |
|
Zhe Jiang Jian Feng Group Co Ltd
SSE:600668
|
CN |
|
Z
|
Zhejiang Aokang Shoes Co Ltd
SSE:603001
|
CN |
|
Kimura Chemical Plants Co Ltd
TSE:6378
|
JP |
|
Deutsche EuroShop AG
XETRA:DEQ
|
DE |
|
Inocycle Technology Group Tbk PT
IDX:INOV
|
ID |
|
B
|
Bal Pharma Ltd
NSE:BALPHARMA
|
IN |
|
P
|
PNB Housing Finance Ltd
BSE:540173
|
IN |
|
KeePer Technical Laboratory Co Ltd
TSE:6036
|
JP |
|
Hylink Digital Solutions Co Ltd
SSE:603825
|
CN |
Shilpa Medicare Ltd
Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.
Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.
Record Revenue & Profit: Shilpa Medicare reported its highest ever quarterly revenue of INR 411 crores, up 28% year-on-year, and highest ever quarterly EBITDA of INR 115 crores, up 41%.
Margin Expansion: Gross margin for the quarter stood at 68%, and EBITDA margin improved to 28% from 26% last year, driven by strong operating leverage.
Strong Formulation Growth: Formulation revenues grew 50% year-on-year to INR 177 crores, with the base business (excluding licensing) up 104% quarter-on-quarter.
International Traction: European formulation sales rose sharply, with Nilotinib showing strong volume growth and limited competition.
Pipeline Progress: Major R&D and product launches across APIs, biologics, peptides, and formulations—including NorUDCA, Rotigotine patch (EU launch in FY '27), and new oncology APIs.
Positive Outlook: Management expects continued growth across all verticals, with major contributions from Biologics and Formulation in FY '27 and improving ROCE.
CapEx & Debt: Ongoing strategic CapEx (~INR 87 crores in Q3) is funded mostly via internal accruals; net debt stands at INR 625 crores, with no plans to increase borrowings.
